Mesoblast Limited
As of Oct 22, 2026, Mesoblast is in Stage 4, the downtrend phase, now in week 3 (since Oct 2, 2026). It closed at $12.55, 40.1% below its 52-week high and below its 200-day average, which is falling.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MESO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MESO among Biotechnology287th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …287 | MESO | Stage 4 · wk 3 | 32 | −17.9% |
Mesoblast: quick answers
What stage is Mesoblast in?
As of Oct 22, 2026, Mesoblast (MESO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Mesoblast in an uptrend?
No. Mesoblast is in a Stage 4 downtrend. It trades 19.4% below its 200-day average, which is falling.
How far is Mesoblast from its 52-week high?
Mesoblast closed at $12.55 on Oct 22, 2026, 40.1% below its 52-week high of $20.96. Its 52-week low is $11.95.
How has Mesoblast performed over the past year?
As of Oct 22, 2026, Mesoblast is down 31.7% over the past year and down 30.9% so far in 2026.
Which sector and industry is Mesoblast in?
Mesoblast is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.